← Back to All US Stocks

Positron Corp. (POSC) Stock Fundamental Analysis & AI Rating 2026

POSC OTC Electromedical & Electrotherapeutic Apparatus TX CIK: 0000844985
Recently Updated • Analysis: Apr 14, 2026 • SEC Data: 2025-12-31
STRONG SELL
95% Conf
Pending
Analysis scheduled

📊 POSC Key Takeaways

Revenue: $461.5K
Net Margin: -2,297.8%
Free Cash Flow: $-4.7M
Current Ratio: 1.39x
Debt/Equity: 0.11x
EPS: $-0.34
AI Rating: STRONG SELL with 95% confidence
Positron Corp. (POSC) receives a STRONG SELL rating with 95% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $461.5K, net profit margin of -2,297.8%, and return on equity (ROE) of -734.4%, Positron Corp. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete POSC stock analysis for 2026.

Is Positron Corp. (POSC) a Good Investment?

Claude

POSITRON CORP is in acute financial distress with severe operational losses (-$10.6M on $461.5K revenue), negative gross margins (-458.2%), and critical cash burn ($4.7M annually) that leaves less than 6 months of runway at current burn rate. The company exhibits fundamental business model failure with no visible path to profitability, deteriorating trends (-345.7% YoY net income decline), and insufficient revenue generation to support operations.

Why Buy Positron Corp. Stock? POSC Key Strengths

Claude
  • + Low financial leverage (Debt/Equity 0.11x) limits bankruptcy risk from creditors
  • + Adequate short-term liquidity ratios (Current 1.39x, Quick 1.11x) provide near-term operating capacity
  • + Minimal debt obligations ($153.7K) reduce fixed interest burden

POSC Stock Risks: Positron Corp. Investment Risks

Claude
  • ! Critical cash runway: $2.5M cash with $4.7M annual operating burn rate implies insolvency within 6-12 months without revenue transformation
  • ! Negative gross margin (-458.2%) indicates fundamental business model failure; losing money on every dollar of sales
  • ! Negligible and stagnant revenue ($461.5K, 0% growth) insufficient to support $4.0M asset base and operational costs; deteriorating losses suggest accelerating decline

Key Metrics to Watch

Claude
  • * Monthly cash burn rate and remaining runway (survival threshold metric)
  • * Revenue growth and gross margin trajectory (path to viability assessment)
  • * Operating cash flow trend (whether losses are stabilizing or accelerating)

Positron Corp. (POSC) Financial Metrics & Key Ratios

Revenue
$461.5K
Net Income
$-10.6M
EPS (Diluted)
$-0.34
Free Cash Flow
$-4.7M
Total Assets
$4.0M
Cash Position
$2.5M

💡 AI Analyst Insight

Positron Corp. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.

POSC Profit Margin, ROE & Profitability Analysis

Gross Margin -458.2%
Operating Margin -2,275.1%
Net Margin -2,297.8%
ROE -734.4%
ROA -265.1%
FCF Margin -1,018.6%

POSC vs Healthcare Sector: How Positron Corp. Compares

How Positron Corp. compares to Healthcare sector averages

Net Margin
POSC -2,297.8%
vs
Sector Avg 12.0%
POSC Sector
ROE
POSC -734.4%
vs
Sector Avg 15.0%
POSC Sector
Current Ratio
POSC 1.4x
vs
Sector Avg 2.0x
POSC Sector
Debt/Equity
POSC 0.1x
vs
Sector Avg 0.6x
POSC Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Positron Corp. Stock Overvalued? POSC Valuation Analysis 2026

Based on fundamental analysis, Positron Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-734.4%
Sector avg: 15%
Net Profit Margin
-2,297.8%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.11x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Positron Corp. Balance Sheet: POSC Debt, Cash & Liquidity

Current Ratio
1.39x
Quick Ratio
1.11x
Debt/Equity
0.11x
Debt/Assets
63.9%
Interest Coverage
-83.76x
Long-term Debt
$153.7K

POSC Revenue & Earnings Growth: 5-Year Financial Trend

POSC 5-year financial data: Year 2025: Revenue $587.5K, Net Income -$2.4M, EPS $-0.09.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Positron Corp.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.09 indicates the company is currently unprofitable.

POSC Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-1,018.6%
Free cash flow / Revenue

POSC Quarterly Earnings & Performance

Quarterly financial performance data for Positron Corp. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2015 $304.0K -$255.0K N/A
Q2 2015 $328.0K -$201.0K N/A
Q1 2015 $346.0K -$554.0K N/A
Q3 2014 $351.0K -$1.4M N/A
Q2 2014 $355.0K -$201.0K N/A
Q1 2014 $371.0K -$861.0K N/A
Q2 2013 $432.0K -$1.1M N/A
Q1 2013 $371.0K -$1.2M N/A

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Positron Corp. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$4.7M
Cash generated from operations
Dividends
None
No dividend program

POSC SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Positron Corp. (CIK: 0000844985)

📋 Recent SEC Filings

Date Form Document Action
Mar 31, 2026 10-K n5417_x4-10k.htm View →
Dec 30, 2025 8-K n5417_x3-8k.htm View →
Dec 16, 2025 8-K n5417_x2-8k.htm View →
Aug 1, 2018 8-K s111767_8k.htm View →
May 10, 2016 8-K v439485_8k.htm View →

Frequently Asked Questions about POSC

What is the AI rating for POSC?

Positron Corp. (POSC) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.

What are POSC's key strengths?

Claude: Low financial leverage (Debt/Equity 0.11x) limits bankruptcy risk from creditors. Adequate short-term liquidity ratios (Current 1.39x, Quick 1.11x) provide near-term operating capacity.

What are the risks of investing in POSC?

Claude: Critical cash runway: $2.5M cash with $4.7M annual operating burn rate implies insolvency within 6-12 months without revenue transformation. Negative gross margin (-458.2%) indicates fundamental business model failure; losing money on every dollar of sales.

What is POSC's revenue and growth?

Positron Corp. reported revenue of $461.5K.

Does POSC pay dividends?

Positron Corp. does not currently pay dividends.

Where can I find POSC SEC filings?

Official SEC filings for Positron Corp. (CIK: 0000844985) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is POSC's EPS?

Positron Corp. has a diluted EPS of $-0.34.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is POSC a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Positron Corp. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is POSC stock overvalued or undervalued?

Valuation metrics for POSC: ROE of -734.4% (sector avg: 15%), net margin of -2,297.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy POSC stock in 2026?

Our dual AI analysis gives Positron Corp. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is POSC's free cash flow?

Positron Corp.'s operating cash flow is $-4.7M, with capital expenditures of $0.0. FCF margin is -1,018.6%.

How does POSC compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -2,297.8% (avg: 12%), ROE -734.4% (avg: 15%), current ratio 1.39 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 14, 2026 | Data as of: 2025-12-31 | Powered by Claude AI